Tight Junction Modulation of the Blood Brain Barrier: CNS Delivery of Small Molecules

Overview

Journal Tissue Barriers

Specialties Anatomy & Histology
Biology
Physiology

Date 2016 May 4

PMID 27141420

Citations 107

Authors

Chris Greene

Matthew Campbell

Affiliations

Soon will be listed here.

Abstract

The blood brain barrier (BBB) represents a major obstacle for targeted drug delivery to the brain for the treatment of central nervous system (CNS) disorders. Significant advances in barrier research over the past decade has led to the discovery of an increasing number of structural and regulatory proteins in tight junctions (TJ) and adherens junctions (AJ). These discoveries are providing the framework for the development of novel TJ modulators which can act specifically and temporarily to alter BBB function and regulate paracellular uptake of molecules. TJ modulators that have shown therapeutic potential in preclinical models include claudin-5 and occludin siRNAs, peptides derived from zonula occludens toxin as well as synthetic peptides targeting the extracellular loops of TJs. Adding to the array of modulating agents are novel mechanisms of BBB regulation such as focused ultrasound (FUS). This review will give a succinct overview of BBB biology and TJ modulation in general. Novel insights into BBB regulation in health and disease will also be summarized.

Citing Articles

Much More than Nutrients: The Protective Effects of Nutraceuticals on the Blood-Brain Barrier in Diseases.

Kocsis A, Kucsapszky N, Santa-Maria A, Hunyadi A, Deli M, Walter F Nutrients. 2025; 17(5).

PMID: 40077636 PMC: 11901837. DOI: 10.3390/nu17050766.

Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology.

Dhariwal R, Jain M, Mir Y, Singh A, Jain B, Kumar P Front Med (Lausanne). 2025; 12:1522223.

PMID: 39963432 PMC: 11831571. DOI: 10.3389/fmed.2025.1522223.

Systematic Review of Pre-Clinical Systems Using Artificial Microenvironments and Anti-Migratory Drugs to Control Migration of Glioblastoma Cells.

Selvi H, Bruning-Richardson A, Danovi D Expert Rev Mol Med. 2025; 27:e6.

PMID: 39844377 PMC: 11803519. DOI: 10.1017/erm.2024.33.

A claudin5-binding peptide enhances the permeability of the blood-brain barrier in vitro.

Trevisani M, Berselli A, Alberini G, Centonze E, Vercellino S, Cartocci V Sci Adv. 2025; 11(2):eadq2616.

PMID: 39792664 PMC: 11721574. DOI: 10.1126/sciadv.adq2616.

Role of P × receptor during focused ultrasound induced blood brain barrier modulation.

Park J, Na Y, Lee J, Seo Y, Kim H, Han S Sci Rep. 2025; 15(1):965.

PMID: 39762398 PMC: 11704064. DOI: 10.1038/s41598-024-83913-3.

References

Butt A, JONES H, Abbott N . Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol. 1990; 429:47-62. PMC: 1181686. DOI: 10.1113/jphysiol.1990.sp018243. View

Nguyen L, Ma D, Shui G, Wong P, Cazenave-Gassiot A, Zhang X . Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 2014; 509(7501):503-6. DOI: 10.1038/nature13241. View

Campbell M, Nguyen A, Kiang A, Tam L, Gobbo O, Kerskens C . An experimental platform for systemic drug delivery to the retina. Proc Natl Acad Sci U S A. 2009; 106(42):17817-22. PMC: 2760489. DOI: 10.1073/pnas.0908561106. View

Saunders N, Liddelow S, Dziegielewska K . Barrier mechanisms in the developing brain. Front Pharmacol. 2012; 3:46. PMC: 3314990. DOI: 10.3389/fphar.2012.00046. View

Itoh M, Sasaki H, Furuse M, Ozaki H, Kita T, Tsukita S . Junctional adhesion molecule (JAM) binds to PAR-3: a possible mechanism for the recruitment of PAR-3 to tight junctions. J Cell Biol. 2001; 154(3):491-7. PMC: 2196413. DOI: 10.1083/jcb.200103047. View

Pardridge W . Transport of nutrients and hormones through the blood-brain barrier. Diabetologia. 1981; 20 Suppl:246-54. View

Lindmark T, Soderholm J, Olaison G, Alvan G, Ocklind G, Artursson P . Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm Res. 1997; 14(7):930-5. DOI: 10.1023/a:1012112219578. View

Park J, Zhang Y, Vykhodtseva N, Jolesz F, McDannold N . The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound. J Control Release. 2012; 162(1):134-42. PMC: 3520430. DOI: 10.1016/j.jconrel.2012.06.012. View

Zhou W, Fong M, Min Y, Somlo G, Liu L, Palomares M . Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014; 25(4):501-15. PMC: 4016197. DOI: 10.1016/j.ccr.2014.03.007. View

10.

Kapural M, Barnett G, Perl J, Masaryk T, Apollo D, Rasmussen P . Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res. 2002; 940(1-2):102-4. DOI: 10.1016/s0006-8993(02)02586-6. View

11.

Wolk R, Gami A, Garcia-Touchard A, Somers V . Sleep and cardiovascular disease. Curr Probl Cardiol. 2005; 30(12):625-62. DOI: 10.1016/j.cpcardiol.2005.07.002. View

12.

Steiner O, Coisne C, Cecchelli R, Boscacci R, Deutsch U, Engelhardt B . Differential roles for endothelial ICAM-1, ICAM-2, and VCAM-1 in shear-resistant T cell arrest, polarization, and directed crawling on blood-brain barrier endothelium. J Immunol. 2010; 185(8):4846-55. DOI: 10.4049/jimmunol.0903732. View

13.

Burgess A, Huang Y, Querbes W, Sah D, Hynynen K . Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression. J Control Release. 2012; 163(2):125-9. PMC: 4010143. DOI: 10.1016/j.jconrel.2012.08.012. View

14.

Rapoport S . Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin Investig Drugs. 2002; 10(10):1809-18. DOI: 10.1517/13543784.10.10.1809. View

15.

Nutt D, Wilson S, Paterson L . Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci. 2008; 10(3):329-36. PMC: 3181883. View

16.

Wong V, Gumbiner B . A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier. J Cell Biol. 1997; 136(2):399-409. PMC: 2134825. DOI: 10.1083/jcb.136.2.399. View

17.

Fanning A, Jameson B, Jesaitis L, Anderson J . The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem. 1998; 273(45):29745-53. DOI: 10.1074/jbc.273.45.29745. View

18.

Wohlfart S, Gelperina S, Kreuter J . Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 2011; 161(2):264-73. DOI: 10.1016/j.jconrel.2011.08.017. View

19.

Blecharz K, Haghikia A, Stasiolek M, Kruse N, Drenckhahn D, Gold R . Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Mult Scler. 2010; 16(3):293-302. DOI: 10.1177/1352458509358189. View

20.

Boado R, Pardridge W . Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos. 2009; 37(12):2299-304. PMC: 2784703. DOI: 10.1124/dmd.109.028787. View